PapersPMID:25335553
Astragalus (a traditional Chinese medicine) for treating chronic kidney disease.
- findings
- 4
- compound
- 1
- endpoints
- 4
- Study, every finding
- meta-analysis
What moved
How to read these marks →- Increases blood haemoglobin concentration
very limited
“Astragalus significantly decreased 24 hour proteinuria at end of treatment (10 studies, 640 participants; MD -0.53 g/24 h, 95% CI -0.79 to -0.26; I² = 90%); significantly increased haemoglobin levels overall (4 studies, 222 participants): MD 9.51 g/L, 95% CI 4.90 to 14.11; I² = 0%) and in haemodialysis patients in particular (3 studies, 142 participants: MD 11.20 g/L, 95% CI 5.81 to 16.59; I² = 0%).”
- Participants
- 222
- Effect
- 9.51 mean difference, 95% CI 4.9 to 14.11
- Population
- People with chronic kidney disease, overall pooled estimate of four trials (the haemodialysis subgroup is reported separately); astragalus against placebo, no treatment or conventional interventions
- Increases serum albumin
very limited
“Astragalus significantly increased serum albumin (9 studies, 522 participants: MD 3.55 g/L, 95% CI 2.33 to 4.78; I² = 65%).”
- Participants
- 522
- Effect
- 3.55 mean difference, 95% CI 2.33 to 4.78
- Population
- People with chronic kidney disease, dialysis and non-dialysis; pooled randomised and quasi-randomised trials of astragalus against placebo, no treatment or conventional interventions
“Astragalus significantly decreased systolic blood pressure (2 studies, 77 participants: MD -16.65 mm Hg, 95% CI -28.83 to -4.47; I² = 50%), and diastolic blood pressure (2 studies, 77 participants: MD -6.02 mm Hg, 95% CI -10.59 to -1.46; I² = 0%).”
- Decreases systolic blood pressure
very limited
- Participants
- 77
- Effect
- −16.65 mean difference, 95% CI −28.83 to −4.47
- Population
- People with chronic kidney disease; two pooled trials; astragalus against placebo, no treatment or conventional interventions
- Decreases diastolic blood pressure
very limited
- Participants
- 77
- Effect
- −6.02 mean difference, 95% CI −10.59 to −1.46
- Population
- People with chronic kidney disease; two pooled trials; astragalus against placebo, no treatment or conventional interventions
Study record
- Design
- meta-analysis
- Species
- human
- Population
- People with chronic kidney disease, of whom 241 were receiving dialysis treatment, in 22 RCTs and quasi-RCTs
- Participants
- 1,323
- Comparator
- no treatment / not stated in the paper
- Duration
- not reported
- Endpoints measured
- 11